dr. joel neal on impact of pd-l1 tests on pembrolizumab, nivolumab efficacy in frontline nsclc
Published 8 years ago • 391 plays • Length 1:18Download video MP4
Download video MP3
Similar videos
-
1:04
dr. neal on ongoing trials of immunotherapy for lung cancer
-
1:06
dr. neal on immunotherapy combinations in lung cancer
-
1:20
dr. neal on exciting advancements in the field of lung cancer
-
1:56
dr. levy on impact of nivolumab, pembrolizumab approvals in nsclc
-
0:35
dr. farago on the fda approval of pembrolizumab for lower pd-1 cutoff nsclc
-
10:20
pd-l1 testing in advanced lung cancer
-
4:41
pd-l1 testing for nsclc
-
3:46
phase iii trial: pembrolizumab for patients w/ metastatic nsclc that expresses pd-1
-
1:02:19
immune checkpoint inhibition and novel therapies for myelodysplastic syndromes/neoplasms
-
26:40
the basic biology of pd-1/pd-l1
-
4:00
cancer immunotherapy - pd-1 and pd-l1
-
5:44
reliability of pd-l1 testing in nsclc
-
3:42
first line pembrolizumab in pd-l1 tps 90% nsclc
-
1:48
results of keynote-024 trial of pembrolizumab in nsclc
-
1:54
dr. wakelee on fda approval of frontline pembrolizumab in nsclc
-
2:56
keynote-010: pembrolizumab, anti-pd-1, for advanced nsclc with pd-l1 expression
-
7:31
outcomes of first-line pembrolizumab monotherapy for pd-l1–positive metastatic nsclc
-
2:30
dr. lopes on the keynote-042 results of frontline pembrolizumab in nsclc
-
2:13
cancer genetics offers the fda-approved pd-l1 testing
-
4:36
efficacy and safety of checkpoint inhibitors in lung cancer
-
0:56
pembrolizumab and the significance of pd-l1 for lung cancer
-
2:03
antibiotics impact outcomes with pembrolizumab in nsclc patients